Trial Profile
Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Vinorelbine (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 17 Feb 2016 New trial record